Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mattheus Thijs van Iersel

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Journal of Clinical Pharmacology|August 18, 2017
The Use of IC<sub>50</sub> for Potency and MTD as Objective in Study BIA 10-2474Mattheus Thijs van Iersel
Journal of Clinical Pharmacology|May 11, 2018
A Change in Posture Significantly Affects Plasma Concentrations of Large Molecules Such as IgG AntibodiesMattheus Thijs van Iersel, Maria I Velinova
Therapeutic Innovation & Regulatory Science|September 21, 2018
Structured Risk Assessment for First-in-Human StudiesMattheus Thijs van Iersel, Howard E Greenberg, Mary L Westrick
Therapeutic Innovation & Regulatory Science|September 21, 2018
Safety in FIH Trials: A Summary of the Symposium "Fatal Drug Trial in Phase 1: Understanding Risk, Subject Safety, Timelines, and Cost"Howard E Greenberg, Mattheus Thijs van Iersel, Mary L Westrick, et al.
Clinical Pharmacology and Therapeutics|November 5, 2020
Pharmacology-Guided Rule-Based Adaptive Dose Escalation in First-in-Human StudiesEwoud-Jan van Hoogdalem, Mattheus Thijs van Iersel, Erica Winter, et al.
Clinical and Translational Science|August 16, 2024
First-in-human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitorHidetoshi Shimizu, Michael A Tortorici, Yoshiyasu Ohta, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Journal of Clinical Pharmacology|August 18, 2017
The Use of IC<sub>50</sub> for Potency and MTD as Objective in Study BIA 10-2474Mattheus Thijs van Iersel
Journal of Clinical Pharmacology|May 11, 2018
A Change in Posture Significantly Affects Plasma Concentrations of Large Molecules Such as IgG AntibodiesMattheus Thijs van Iersel, Maria I Velinova
Therapeutic Innovation & Regulatory Science|September 21, 2018
Structured Risk Assessment for First-in-Human StudiesMattheus Thijs van Iersel, Howard E Greenberg, Mary L Westrick
Therapeutic Innovation & Regulatory Science|September 21, 2018
Safety in FIH Trials: A Summary of the Symposium "Fatal Drug Trial in Phase 1: Understanding Risk, Subject Safety, Timelines, and Cost"Howard E Greenberg, Mattheus Thijs van Iersel, Mary L Westrick, et al.
Clinical Pharmacology and Therapeutics|November 5, 2020
Pharmacology-Guided Rule-Based Adaptive Dose Escalation in First-in-Human StudiesEwoud-Jan van Hoogdalem, Mattheus Thijs van Iersel, Erica Winter, et al.
Clinical and Translational Science|August 16, 2024
First-in-human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitorHidetoshi Shimizu, Michael A Tortorici, Yoshiyasu Ohta, et al.
Pageof 1